Beamr video compression achieves up to 50% improvement for AVs
Lyell Immunopharma, Inc. (NASDAQ:LYEL), a biotech company currently valued at $163.39 million, reported insider trading activity from Chief Operating Officer Stephen J. Hill on August 11 and August 12. The sales totaled $1,929. According to InvestingPro analysis, the company appears undervalued at its current price of $10.83.
On August 11, Hill sold 91 shares of Lyell Immunopharma at a weighted average price of $10.526, for a total value of approximately $958. The price for these shares ranged from $10.045 to $11.00. Following this transaction, Hill directly owns 8,943 shares, which includes 390 shares acquired through the company’s Employee Stock Purchase Plan. InvestingPro data shows the company maintains a strong balance sheet with more cash than debt, though it’s currently experiencing rapid cash burn.
The following day, August 12, Hill sold 94 shares at a weighted average price of $10.338, for a total value of approximately $970. The price for these shares ranged from $10.120 to $10.415. Following this transaction, Hill directly owns 8,849 shares.
The sales were executed to cover tax withholding obligations arising from the settlement of vested restricted stock units.
All share and amounts reported reflect a 1-for-20 reverse stock split effected by Lyell Immunopharma on May 30, 2025.
In other recent news, Lyell Immunopharma has announced a securities purchase agreement that could raise up to $100 million through a private placement with institutional and accredited investors. The company expects an initial closing of approximately $50 million of common stock, priced at $13.32 per share, around July 25, 2025, pending customary closing conditions. Additionally, Lyell Immunopharma released promising data regarding its LYL314 therapy for large B-cell lymphoma. The therapy demonstrated an 88% overall response rate and a 72% complete response rate in a Phase 1/2 trial involving patients in the third- or later-line treatment setting. Notably, 71% of patients who achieved a complete response maintained this status for at least six months. These developments highlight the company’s ongoing efforts in advancing its clinical-stage therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.